Cyprodinil


Curated chemical-gene interactions from CTD
Entrez gene IDGene symbolInteraction typeReference
11199 ANXA10 Increases expression PMID:32194361
1509 CTSD Increases expression PMID:26344002
1543 CYP1A1 Increases expression PMID:23228475; PMID:23228475; PMID:32194361; PMID:32194361
15495 HSD3B4 Decreases activity PMID:36470526
1557 CYP2C19 Decreases expression PMID:32194361
1581 CYP7A1 Decreases expression PMID:32194361
196 AHR Decreases expression PMID:23228475
196 AHR Increases activity PMID:23436777; PMID:28728110
2099 ESR1 Increases activity PMID:33352482
2538 G6PC1 Decreases expression PMID:32194361
2876 GPX1 Affects expression PMID:22880100
367 AR Increases activity PMID:28803809
367 AR Increases expression PMID:21310686
383 ARG1 Decreases expression PMID:32194361
4899 NRF1 Increases expression PMID:33352482
5111 PCNA Increases expression PMID:26344002
595 CCND1 Increases expression PMID:26344002
6286 S100P Increases expression PMID:32194361
7031 TFF1 Increases expression PMID:33352482
836 CASP3 Increases expression PMID:22880100
8856 NR1I2 Increases activity PMID:28728110
898 CCNE1 Increases expression PMID:26344002

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.